Bureau of International Labor Affairs: Labor Advisory Committee for Trade Negotiations and Trade Policy, 9615-9616 [2010-4352]
Download as PDF
Federal Register / Vol. 75, No. 41 / Wednesday, March 3, 2010 / Notices
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated October 16, 2009, and
published in the Federal Register on
October 28, 2009, (74 FR 55587),
American Radiolabeled Chemical, Inc.,
101 Arc Drive, St. Louis, Missouri
63146, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
mstockstill on DSKH9S0YB1PROD with NOTICES
[FR Doc. 2010–4403 Filed 3–2–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances as radiolabeled compounds
for biochemical research.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
American Radiolabeled Chemical, Inc.
to manufacture the listed basic classes
of controlled substances is consistent
with the public interest at this time.
DEA has investigated American
Radiolabeled Chemical Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
16:08 Mar 02, 2010
Dated: February 24, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Schedule
Gamma
Hydroxybutyric
Acid
(2010) ........................................
Ibogaine (7260) ............................
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) ......
Dimethyltryptamine (7435) ...........
1-[1-(2–
Thienyl)cyclohexyl]piperidine
(7470) ........................................
Dihydromorphine (9145) ...............
Normorphine (9313) .....................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Amobarbital (2125) .......................
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Metazocine (9240) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273) ...............
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ....................
Phenazocine (9715) .....................
Fentanyl (9801) ............................
VerDate Nov<24>2008
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Jkt 220001
Drug Enforcement Administration
Manufacturer of Controlled
Substances Notice of Registration
By Notice dated October 21, 2009, and
published in the Federal Register on
October 28, 2009, (74 FR 55588),
Johnson Matthey Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066–1742, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
schedules I and II:
Drug
Frm 00044
Fmt 4703
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey Inc. to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Johnson Matthey Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: February 24, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2010–4404 Filed 3–2–10; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Office of the Secretary
Schedule
Gamma
Hydroxybutyric
Acid
(2010) ........................................
Tetrahydrocannabinols (7370) ......
Dihydromorphine (9145) ...............
Difenoxin (9168) ...........................
Propiram (9649) ............................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Nabilone (7379) ............................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ....................
Noroxymorphone (9668) ...............
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
PO 00000
9615
Sfmt 4703
Bureau of International Labor Affairs:
Labor Advisory Committee for Trade
I Negotiations and Trade Policy
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
ACTION:
Meeting Notice.
SUMMARY: Pursuant to the provisions of
the Federal Advisory Committee Act
(Pub. L. 92–463, as amended), notice is
hereby given of a meeting of the Labor
Advisory Committee for Trade
Negotiation and Trade Policy.
Date, Time, Place: March 16, 2010;
10:30 a.m.–11:30 a.m.; U.S. Department
of Labor, Secretary’s Conference Room,
200 Constitution Ave., NW.,
Washington, DC.
Purpose: The meeting will include a
review and discussion of current issues
which influence U.S. trade policy.
Potential U.S. negotiating objectives and
bargaining positions in current and
anticipated trade negotiations will be
discussed. Pursuant to 19 U.S.C. 2155(f)
it has been determined that the meeting
will be concerned with matters the
disclosure of which would seriously
compromise the Government’s
negotiating objectives or bargaining
E:\FR\FM\03MRN1.SGM
03MRN1
9616
Federal Register / Vol. 75, No. 41 / Wednesday, March 3, 2010 / Notices
positions. Accordingly, the meeting will
be closed to the public.
FOR FURTHER INFORMATION CONTACT:
Gregory Schoepfle, Director, Office of
Trade and Labor Affairs; Phone: (202)
693–4887.
Signed at Washington, DC, the 25th day of
February 2010.
Sandra Polaski,
Deputy Undersecretary, International Affairs.
[FR Doc. 2010–4352 Filed 3–2–10; 8:45 am]
BILLING CODE 4510–28–P
NATIONAL SCIENCE FOUNDATION
Committee Management Renewals
The NSF management officials having
responsibility for three advisory
committees listed below have
determined that renewing these groups
for another two years is necessary and
in the public interest in connection with
the performance of duties imposed upon
the Director, National Science
Foundation (NSF), by 42 U.S.C. 1861 et
seq. This determination follows
consultation with the Committee
Management Secretariat, General
Services Administration.
Committees:
Advisory Committee for Environmental
Research and Education, #9487.
Proposal Review Panel for Industrial
Innovations and Partnerships, #28164.
Proposal Review Panel for Emerging
Frontiers in Research and Innovation,
#34558.
Effective date for renewal is March 1,
2010. For more information, please
contact Susanne Bolton, NSF, at (703)
292–7488.
Susanne Bolton,
Committee Management Officer.
[FR Doc. 2010–4233 Filed 3–2–10; 8:45 am]
BILLING CODE 7555–01–P
NUCLEAR REGULATORY
COMMISSION
mstockstill on DSKH9S0YB1PROD with NOTICES
[Docket Nos. 50–266 and 50–301; NRC–
2010–0078]
FPL Energy Point Beach, LLC; Notice
of Consideration of Issuance of
Amendment to Facility Operating
License, Proposed No Significant
Hazards Consideration Determination,
and Opportunity for a Hearing
The U.S. Nuclear Regulatory
Commission (the Commission) is
considering issuance of an amendment
to Renewed Facility Operating License
Nos. DPR–24 and DPR–27 issued to FPL
Energy Point Beach, LLC (the licensee)
VerDate Nov<24>2008
16:08 Mar 02, 2010
Jkt 220001
for operation of the Point Beach Nuclear
Plant, Units 1 and 2 located in the Town
of Two Creeks, Manitowoc County,
Wisconsin.
On July 14, 2009, the Nuclear
Regulatory Commission published a
Notice of Consideration of Issuance,
Proposed No Significant Hazards
Consideration Determination, and
Opportunity for Hearing in the Federal
Register (74 FR 34048) for a proposed
amendment that would change the legal
name of the licensee and owner from
‘‘FPL Energy Point Beach, LLC’’ to
‘‘NextEra Energy Point Beach, LLC.’’
On January 19, 2010, the licensee
submitted a supplement which
expanded the original scope of work.
The proposed revisions would correct
an administrative error within a License
Condition contained in Appendix C of
the Renewed Facility Operating
Licenses. The correction changes ‘‘FPLE
Group Capital’’ to the appropriately
titled ‘‘FPL Group Capital.’’
Before issuance of the proposed
license amendment, the Commission
will have made findings required by the
Atomic Energy Act of 1954, as amended
(the Act), and the Commission’s
regulations.
The Commission has made a
proposed determination that the
amendment request involves no
significant hazards consideration. Under
the Commission’s regulations in Title 10
of the Code of Federal Regulations (10
CFR), Section 50.92, this means that
operation of the facility in accordance
with the proposed amendment would
not (1) involve a significant increase in
the probability or consequences of an
accident previously evaluated; or (2)
create the possibility of a new or
different kind of accident from any
accident previously evaluated; or (3)
involve a significant reduction in a
margin of safety. As required by 10 CFR
50.91(a), the licensee has provided its
analysis of the issue of no significant
hazards consideration, which is
presented below:
1. Does the proposed amendment involve
a significant increase in the probability or
consequences of an accident previously
evaluated?
Response: No.
This request is for administrative changes
only. No actual facility equipment or
accident analyses will be affected by the
proposed changes. Therefore, this request
will have no impact on the probability or
consequences of an accident previously
evaluated.
2. Does the proposed amendment create
the possibility of a new or different kind of
accident from any accident previously
evaluated?
Response: No.
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
This request is for administrative changes
only. No actual facility equipment or
accident analyses will be affected by the
proposed changes and no failure modes not
bounded by previously evaluated accidents
will be created. Therefore, this request will
not create the possibility of a new or different
kind of accident from any accident
previously evaluated.
3. Does the proposed amendment involve
a significant reduction in a margin of safety?
Response: No.
Margin of safety is associated with
confidence in the ability of the fission
product barriers (i.e., fuel cladding, reactor
coolant system pressure boundary, and
containment structure) to limit the level of
radiation dose to the public. This request is
for administrative changes only. No actual
plant equipment or accident analyses will be
affected by the proposed changes.
Additionally, the proposed changes will not
relax any criteria used to establish safety
limits, will not relax any safety system
settings, and will not relax the bases for any
limiting conditions of operation. Therefore,
these proposed changes will not involve a
significant reduction in a margin of safety.
The NRC staff has reviewed the
licensee’s analysis and, based on this
review, it appears that the three
standards of 10 CFR 50.92(c) are
satisfied. Therefore, the NRC staff
proposes to determine that the
amendment request involves no
significant hazards consideration.
The Commission is seeking public
comments on this proposed
determination. Any comments received
within 30 days after the date of
publication of this notice will be
considered in making any final
determination.
Normally, the Commission will not
issue the amendment until the
expiration of 60 days after the date of
publication of this notice. The
Commission may issue the license
amendment before expiration of the 60day period provided that its final
determination is that the amendment
involves no significant hazards
consideration. In addition, the
Commission may issue the amendment
prior to the expiration of the 30-day
comment period should circumstances
change during the 30-day comment
period such that failure to act in a
timely way would result, for example,
in derating or shutdown of the facility.
Should the Commission take action
prior to the expiration of either the
comment period or the notice period, it
will publish in the Federal Register a
notice of issuance. Should the
Commission make a final No Significant
Hazards Consideration Determination,
any hearing will take place after
issuance. The Commission expects that
the need to take this action will occur
very infrequently.
E:\FR\FM\03MRN1.SGM
03MRN1
Agencies
[Federal Register Volume 75, Number 41 (Wednesday, March 3, 2010)]
[Notices]
[Pages 9615-9616]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-4352]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF LABOR
Office of the Secretary
Bureau of International Labor Affairs: Labor Advisory Committee
for Trade Negotiations and Trade Policy
ACTION: Meeting Notice.
-----------------------------------------------------------------------
SUMMARY: Pursuant to the provisions of the Federal Advisory Committee
Act (Pub. L. 92-463, as amended), notice is hereby given of a meeting
of the Labor Advisory Committee for Trade Negotiation and Trade Policy.
Date, Time, Place: March 16, 2010; 10:30 a.m.-11:30 a.m.; U.S.
Department of Labor, Secretary's Conference Room, 200 Constitution
Ave., NW., Washington, DC.
Purpose: The meeting will include a review and discussion of
current issues which influence U.S. trade policy. Potential U.S.
negotiating objectives and bargaining positions in current and
anticipated trade negotiations will be discussed. Pursuant to 19 U.S.C.
2155(f) it has been determined that the meeting will be concerned with
matters the disclosure of which would seriously compromise the
Government's negotiating objectives or bargaining
[[Page 9616]]
positions. Accordingly, the meeting will be closed to the public.
FOR FURTHER INFORMATION CONTACT: Gregory Schoepfle, Director, Office of
Trade and Labor Affairs; Phone: (202) 693-4887.
Signed at Washington, DC, the 25th day of February 2010.
Sandra Polaski,
Deputy Undersecretary, International Affairs.
[FR Doc. 2010-4352 Filed 3-2-10; 8:45 am]
BILLING CODE 4510-28-P